Celltrion is expanding its market influence in Asia, maintaining the top prescription share for its key products, including autoimmune disease treatments and cancer drugs.
According to IQVIA, a pharmaceutical market research firm, Celltrion's autoimmune disease treatment 'Remsima' (ingredient: infliximab) recorded a 93% market share in Singapore for the first quarter of this year. It also led in market share in Hong Kong (84%), Thailand (78%), and Malaysia (72%).
The company's cancer drug portfolio also remains strong in major markets. The blood cancer treatment 'Truxima' (rituximab) achieved a 93% market share in Singapore and 78% in Thailand.
The breast and stomach cancer treatment 'Herceptin' (trastuzumab) maintained significant prescription shares of 51% in Malaysia and 42% in Thailand.
Notably, the metastatic colorectal and breast cancer treatment 'Zejula' (bevacizumab) showed rapid growth in the Malaysian market. It ranked fourth among local bevacizumab products in the fourth quarter of last year but surged to a 30% market share in the first quarter of this year, claiming the top position.
Celltrion operates a direct sales system through local subsidiaries in key Asian markets such as Malaysia, Singapore, and Thailand, tailoring its sales and marketing strategies to the specific medical environments and bidding characteristics of each country.
By leveraging its direct sales system through local subsidiaries, Celltrion aims to ensure supply stability and expand its bidding success while enhancing product awareness through local academic conferences and key medical personnel networks.
The company also plans to continue launching new products. In the second half of this year, Celltrion intends to release the allergy treatment 'Omniclone' (omalizumab) and the bone disease treatment 'Stoboclo-Osenbelt' (denosumab) in Thailand.
In Malaysia and Singapore, the company plans to introduce the autoimmune disease treatment 'Stekima' (ustekinumab) within the year, further expanding its product lineup in the Asian region.
Celltrion aims to apply the local sales networks and market expertise gained from existing product sales to new products, driving both revenue growth and profitability improvements.
A Celltrion representative stated, "Our key products, including Remsima, continue to hold the number one market share in major Asian countries, enhancing our market influence. We will strengthen our sales activities to ensure that the success of our existing products translates into new product performance, accelerating growth in the Asian region."
Earlier this year, Celltrion projected its expected revenue for the year at 5.3 trillion won. Analysts believe that exceeding this target is possible. SK Securities has revised its forecast for Celltrion's expected performance to 5.5621 trillion won in revenue and 1.7844 trillion won in operating profit.
According to IQVIA, a pharmaceutical market research firm, Celltrion's autoimmune disease treatment 'Remsima' (ingredient: infliximab) recorded a 93% market share in Singapore for the first quarter of this year. It also led in market share in Hong Kong (84%), Thailand (78%), and Malaysia (72%).
The company's cancer drug portfolio also remains strong in major markets. The blood cancer treatment 'Truxima' (rituximab) achieved a 93% market share in Singapore and 78% in Thailand.
The breast and stomach cancer treatment 'Herceptin' (trastuzumab) maintained significant prescription shares of 51% in Malaysia and 42% in Thailand.
Notably, the metastatic colorectal and breast cancer treatment 'Zejula' (bevacizumab) showed rapid growth in the Malaysian market. It ranked fourth among local bevacizumab products in the fourth quarter of last year but surged to a 30% market share in the first quarter of this year, claiming the top position.
Celltrion operates a direct sales system through local subsidiaries in key Asian markets such as Malaysia, Singapore, and Thailand, tailoring its sales and marketing strategies to the specific medical environments and bidding characteristics of each country.
By leveraging its direct sales system through local subsidiaries, Celltrion aims to ensure supply stability and expand its bidding success while enhancing product awareness through local academic conferences and key medical personnel networks.
The company also plans to continue launching new products. In the second half of this year, Celltrion intends to release the allergy treatment 'Omniclone' (omalizumab) and the bone disease treatment 'Stoboclo-Osenbelt' (denosumab) in Thailand.
In Malaysia and Singapore, the company plans to introduce the autoimmune disease treatment 'Stekima' (ustekinumab) within the year, further expanding its product lineup in the Asian region.
Celltrion aims to apply the local sales networks and market expertise gained from existing product sales to new products, driving both revenue growth and profitability improvements.
A Celltrion representative stated, "Our key products, including Remsima, continue to hold the number one market share in major Asian countries, enhancing our market influence. We will strengthen our sales activities to ensure that the success of our existing products translates into new product performance, accelerating growth in the Asian region."
Earlier this year, Celltrion projected its expected revenue for the year at 5.3 trillion won. Analysts believe that exceeding this target is possible. SK Securities has revised its forecast for Celltrion's expected performance to 5.5621 trillion won in revenue and 1.7844 trillion won in operating profit.
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.